Kornimate/medical-research-clean huggingface dataset:
the effect of conscious sedation on acute stress

Conditions: Dental Anxiety; Dental Fear; Tooth Extraction Status Nos

Summary: the specific aims of the present study were to evaluate saa responses to impacted third molar extractions at different time points in the patients under conscious sedation with local anesthesia and to examine the relationship between saa, conscious sedation and dental anxiety. the null hypothesis was that conscious sedation could be considered to reduce salivary alpha amylase level during the wisdom tooth surgery.

in oral and maxillofacial surgery, surgical extraction of impacted third molars is one of the most common surgical techniques performed in the oral cavity. conscious intravenous sedation could be administered for the patients to provide anxiolysis, sedation, and analgesia for the patient. salivary alpha-amylase (saa) which reflect stress-related changes in the autonomic nervous system (ans), has been proposed as a non-invasive stress biomarker. the aim of the present study was to investigate whether salivary alpha amylase (saa) levels could be decreased by conscious sedation in the patients undergoing impacted third molar extraction. a total of 18 male patients were recruited. all patients were administered modified dental anxiety scale (mdas) test. patients were divided into two groups: test group (procedures under sedation) and control group (procedures under local anesthesia). the following parameters were monitored at different study time-points: systolic blood pressure (sbp), diastolic blood pressure (dbp), oxygen saturation (so2), and heart rate (hr). five samples of saliva were taken from each patient: the first time patient came to clinic, the patient sat in the chair for extraction, before local anesthesia, immediately after extraction, at 4 h after extraction. the concentrations of saa were measured and compared across the different stages of the study between two groups.

Eligibility criteria:
inclusion criteria: * man * 18-35 years * individuals without chemotherapy or radiotherapy history * individuals without antibiotics and nsaids history in the last month * individuals without any medications that affect saliva content in the last 1 month * individuals without corticosteroid treatment history * nonsmokers * wisdom tooth which is indicated to extract * individuals without acute infectious lesion in the mouth * individuals without alcohol or substance abuse * individuals without inflammatory bone disease exclusion criteria: * woman * individuals with any systemic disorders * individuals with chemotherapy and radiotherapy history * individuals with antibiotics and nsaids history in the last month * individuals with use of antibiotics and nsaids history in the last month * individuals with corticosteroid treatment history * smokers * individuals with acute infectious lesion in the mouth * individuals with inflammatory bone disease * individuals with alcohol or substance abuse
in vivo confocal microscopy of cutaneous neoplasms and normal skin

Conditions: Skin Cancer

Summary: the purpose of this study is to investigate new non-invasive imaging techniques for the evaluation of skin lesions, as well as normal skin. our primary goal is to collect and study these images of different skin lesions along with matching biopsy specimens. the long-term goal is to develop a technique that will improve the early detection of skin cancer and eliminate the need for many skin biopsies. the high-resolution oct (apollo medical optics) device can provide both cross-sectional and en-face images with cellular information. real-time color images through the same objective with oct are also provided to show the oct imaging location of lesion. the color image can be registered simultaneously on a larger dermoscopic image obtained by an external dermoscope. the imaging mode of cross-sectional, en-face and color image can be switched arbitrarily to align the lesion and obtain high-resolution images efficiently. the total imaging time is around 10 to 15 minutes depending on the number of images to be obtained. to help identify more diagnostic features of optical imaging and better understand their histology correlation, we have developed a novel technique called "precision biopsy". precision biopsy is an optical imaging guided, feature-targeted mini-biopsy. once the feature of interest is identified and isolated by the optical imaging, a 2.0 mm punch biopsy is performed. besides cosmetic benefit of minimal scarring, this tissue sparing biopsy captures the "feature of interest" for histology revelation. additionally, the histologic features of precision biopsy will be compared to images gathered by multi-modal optical imaging. the precision biopsy will also be compared to the traditional shave biopsy or shave excision, to determine whether the diagnostic information is comparable between the two methods. for live remote control (lrc) imaging consultation, msk dermatologist will based on his clinical examination. an imaging technician will perform the clinical and dermoscopic imaging, while the expert reader will perform confocal imaging remotely via a hippa compliant webex platform.


Eligibility criteria:
inclusion criteria: * patients older than or equal to 10 years of age. * patients with a skin lesion with anticipated epidermal and superficial dermal histologic alterations amenable to visualization by surface confocal microscopy. * healthy volunteer subjects older than or equal to 10 years old. * ability to give informed consent. exclusion criteria: * patients who are allergic to fluorescein sodium.
volunteering as an intervention to reduce depression among adolescents

Conditions: Depression; Adolescent Behavior; Depressive Symptoms

Summary: the purpose of the present study is to test in a preliminary manner an innovative strategy for treating depression among adolescents (alongside existing therapy) using community volunteerism.

the purpose of the present study is to test in a preliminary manner an innovative strategy for treating depression among adolescents (alongside existing therapy) using community volunteerism. in addition, this study will test a potential mechanism by which volunteering might decrease depressive symptoms: increasing psychosocial assets, specifically decreasing self-orientation and increasing an orientation toward others. this will be measured through self-report as well as using functional magnetic resonance imaging (fmri). this study will be the first study to explore how neural response patterns are potentially altered by intense experiences with volunteerism among depressed adolescents.

Eligibility criteria:
inclusion criteria: * age 14-20 * new mild to moderate depression diagnosis (single episode) * new mild to moderate anxiety diagnosis * new adjustment disorder diagnosis * have been in treatment for \< 8 months * right-handed exclusion criteria: * history of recurrent depressive, anxiety or adjustment disorder episodes * have been in treatment \> 8 months * left-handed * expressing suicidal ideation * claustrophobia * any contraindications for completing an mri scan

Keywords: adolescents fmri volunteerism
pulsed electromagnetic field treatment in patients with alzheimer's disease

Conditions: Alzheimer Disease

Summary: an open label pilot study in mild to moderate ad patients to assess the effects of treatment with echs ad pulsed electromagnetic treatment device on disease progression. enrolled patients will receive active devices. they will treat themselves at home three times a day for 15 minutes over 120 days. primary end points are the the alzheimer's disease assessment scale-cognitive subscale and the mini-mental state exam. participants will be followed-up for 9 months post-treatment.


Eligibility criteria:
inclusion criteria: 1. age ≥ 50 years 2. patients diagnosed with mild to moderate alzheimer's dementia defi 3. at least an eighth grade of educational achievement 4. if female, post-menopausal. 5. mmse score between 16 and 26 6. capable of providing consent or having a surrogate (e.g., spouse, family member) capable of providing consent if participant lacks consent capacity 7. able and willing to comply with the protocol 8. if the participant is receiving a cholinesterase inhibitor and/or memantine, such medication has been prescribed for at least 3 months prior to screening and the dose is stable for at least 60 days prior to screening (that dose needs to be maintained throughout the period of this study) 9. spouse, family member or professional caregiver agree and are capable of taking care of the participation of the patient in the study (answering questions regarding the patient's condition, assuming responsibility for medication, and applying and supervising the daily pemf treatments) 10. physical clearance for study participation as evaluated by the clinician exclusion criteria: 1. the patient lacks capacity to consent to study participation and no surrogate is available to provide consent 2. history of epileptic seizures or epilepsy 3. currently taking medication that lowers the seizure threshold 4. presence of depression, bipolar disorder, a psychotic disorder, or any other neurological or psychiatric condition (whether now or in the past), which the investigator finds as interfering with the study 5. severe agitation that would interfere with study procedures 6. alcoholism or substance use disorder as defined by diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) within last 5 years (addicted more than one year and or in remission less than 3 years) or severe sleep deprivation 7. major surgery (defined as any major abdominal, vascular or thoracic surgery requiring general anesthesia and resulting in a period of \>1 week hospitalization) within 4 weeks 8. head anatomy that interferes with the fit of the treatment device 9. participation in another clinical trial within the previous 30 days 10. metal implants in the head, (i.e., cochlear implants, implanted brain stimulators and neurostimulators, aneurysm clips) with the exception of metal implants in mouth
cryoprobe transbronchial lung biopsy in lung transplant patients

Conditions: Lung Transplantation

Summary: lung transplant recipients undergo bronchoscopy with biopsies for clinical indications and for surveillance in the diagnosis of acute rejection using standard transbronchial forceps. it is recognized that standard forceps biopsies underestimate the presence or degree of airway rejection due to crush artifact and sample size. transbronchial cryobiopsies have been shown in the literature to provide larger samples without crush artifact in a safe fashion in lung cancer patients. the aim of this study is to determine if transbronchial cryobiopsy is superior to standard transbronchial forceps biopsies in regards to sample size, architecture and the diagnosis of early rejection in lung transplant recipients which if discovered earlier may improve survival.


Eligibility criteria:
inclusion criteria: * individuals referred for either clinically indicated or surveillance flexible bronchoscopy will be included in the study population * age greater than 18 years and having undergone bilateral orthotopic lung transplantation exclusion criteria: * coagulopathy: plts \ 1.5 * forced expiratory volume at one second (fev1) \< 0.8 * diffuse bullous disease * hemodynamic instability * severe hypoxemia

Keywords: lung transplantation acute rejection
sex differences in vascular responses to exercise

Conditions: Aging

Summary: a key early event in cardiovascular disease development is endothelial dysfunction, characterized by impaired flow-mediated dilation. regular aerobic exercise ameliorates endothelial dysfunction in healthy older men, but the data in healthy postmenopausal women are inconsistent with many studies showing no effect. the primary objective of this study was to examine sex differences in acute and chronic endothelial responses to exercise training in older men vs. older postmenopausal women.


Eligibility criteria:
inclusion criteria: * adults able to give consent * men and women * women must be postmenopausal (either natural or surgical) * 60 to 79 years of age exclusion criteria: * any relevant cardiovascular diseases (e.g., history of coronary artery bypass surgery or angioplasty, or heart failure, myocardial infarction, angina pectoris, peripheral arterial disease) * myocardial ischemia during maximal graded exercise test * major chronic clinical disease (e.g., diabetes, renal or hepatic disease or infection with hepatitis b, c, or hiv) * seizures, or other relevant on-going or recurrent illness * recent (within 3 months) or recurrent hospitalizations * systolic blood pressure \< 100 mmhg * body mass index \> 35 kg/m\^2 * \>5% weight change in past 3 months or unwilling to remain weight stable during study participation * use of tobacco products including smoking traditional or e-cigarettes * use of hormone replacement therapy in women or men (e.g., estrogen, progesterone or testosterone) * regular aerobic exercise training (≥30 min/session and ≥ 3 days/week)

Keywords: high-intensity interval training aerobic exercise acute exercise
vicis - vienna cirrhosis study

Conditions: Liver Cirrhosis; Portal Hypertension; Ascites; Variceal Hemorrhage; Hepatic Encephalopathy

Summary: patients with advanced chronic liver diseases treated at the vienna general hospital of the medical university of vienna will be offered to participate in this prospective observational trial. clinical parameters and laboratory parameters will be recorded for all patients and patients will undergo a regular follow-up schedule with clinical visits at the vienna general hospital. this study is linked to a biobank with serum/plasma, ascitic fluid, urine, gi tract mucosal biopsies, liver biopsies and stool collected from the study participants.

patients with advanced chronic liver disease (acld) as evident by hvpg\>5mmhg or liver biopsy showing f3/f4 fibrosis or as suggested by liver stiffness measurement (lsm) ≥10kpa can be included in the vicis study. in fact most patients will be recruited on the day of hvpg measurement for screening for clinically significant portal hypertension (csph) or on the day of upper gi endoscopy for screening for the presence of varices. next to the detailled characterization of patient characteristics by epidemiologic, clinical and laboratory parameters, the degree of portal hypertension will be assessed by hvpg, liver stiffness will be assessed by transient elastography, the presence of ascites, splenomegaly, portosystemic collaterals, pvt and liver lesions will be assessed by ultrasound. in addition, the included patients will be asked to participate in biobank sampling including serum/plasma, ascitic fluid, urine, gi tract mucosal biopsies, stool, liver biopsies and stool. all patients recruited in the vicis study will be prospectively followed every 3 months (decompenated acld) or every 6 months (compensated acld) patients with clinical visits at the cirrhosis outpatient clinic at the vienna general hospital. these assessments include the recording of decompensating events (such as ascites, hepatic encephalopathy, variceal bleeding), screening for pvt and hcc, and recording of medications.

Eligibility criteria:
inclusion criteria: * age \>18 years and \<100 years * diagnosis of advanced chronic liver disease (by liver stiffness ≥10kpa, hvpg\>5mmhg or histology f3/f4) * written informed consent exclusion criteria: * withdrawal of written informed consent

Keywords: liver cirrhosis portal hypertension
use of prp in endometrial reconstruction

Conditions: Asherman Syndrome; Endometrial Atrophy

Summary: infertility, which affected 48.5 million couples worldwide in 2010 alone, has many causes; some causes result from issues related to the endometrium. unfortunately, no cure exists for medical conditions resulting in the destruction of the endometrium, or for non-functional uterus. thus, safe and effective therapies are needed to treat these diseases and to establish fertility in affected women. these novel techniques refer to the use and application of regenerative/paracrine factors to regenerate the endometrium in patients with asherman's syndrome (as) and endometrial atrophy (ea).these new therapies based on the injection of the identified regenerative/paracrine factors and the platelet-rich plasma (prp) from whole blood in an immunodeficient mouse model with as/ea, evaluating their contribution and/or effect in the endometrial repair by functional proofs.

the objective is to know the effect of these regenerative factors obtained from platelet-rich plasma in an immunodeficient murine model with as/ea blood from patients with asherman's syndrome (as) and endometrial atrophy (ea) will be collected, maintained under anticoagulant solution and after several centrifugations prp will be obtained. demonstration of a functional endometrium will be proved determining pregnancy and implantation rates as well as the number of live pups/pregnant female in our mice model. also, the uterus histology will be analysed in treated and untreated mice

Eligibility criteria:
inclusion criteria: * participants diagnosed with asherman syndrome and endometrial atrophy by hysteroscopy. * no pregnancy after hormonal treatment. exclusion criteria: * psychiatric diseases.

Keywords: platelet-rich plasma cell therapy regenerative factors autologous treatment paracrine factors
prevalence of the c.853delt mutation of the hoxb13 gene in prostate cancer in martinique

Conditions: Prostate Cancer

Summary: in martinique, prostate cancer incidence rates are nowadays among the highest worldwide with a high incidence of early-onset and familial forms. we identified a rare heterozygous germline variant c.853delt (p.ter285lysfs) rs77179853, reported only among patients of african ancestry with a minor allele frequency of 3.2%. we search to estimate the prevalence of this variant in a sample of prevalent prostate cancer cases managed in urology consultation in martinique .

in martinique, prostate cancer incidence rates are nowadays among the highest worldwide with a high incidence of early-onset and familial forms. despite the demonstration of a strong familial component, identification of the genetic basis for hereditary prostate cancer is challenging. the screening of the hoxb13 gene is recommended for men who develop an early-onset and/or familial pca . in fact, the hoxb13 germline variant g84e (rs138213197) was described in men of european descent with prostate cancer risk. other germline variants were detected in ethnic groups. more recently, we reported a rare hoxb13 mutation, specifically c.853delt (pter285lysfs) that appears to be contribute to young prostate cancer cases in martinique. this variant is a stop loss reported only among patients of african ancestry . regarding the allele frequency of the hoxb13 c.853delt variant observed in the pca cohort, it will be necessary to assess relative and absolute pca risks for hoxb13 c.853delt carriers. this information is essential to use this variant in genetic counseling. we propose to sequence the hoxb13 gene of all prostate cancers cases managed in urology consultation in martinique.

Eligibility criteria:
inclusion criteria: * adult man over 18 years of age living in martinique with a prostate cancer whatever the histological type and the stage, managed in urology consultation (public and private sectors of martinique) * sporadic or familial form * informed with a written consent signed by the participant and the investigator * affiliate or beneficiary of french social security. exclusion criteria: * patient who is not of african descent * refusal to participate. * patients not affiliated to french social security

Keywords: prostate cancer martinique hoxb13 c.853delt prevalence
examining social, emotional, and cognitive functioning in people with fragile x and down syndromes

Conditions: Anxiety Disorders; Child Developmental Disorders, Pervasive

Summary: by testing physiological responses to anxiety in people with nervous system developmental disorders, this study will identify specific physiological characteristics associated with response to anxiety treatments.

anxiety is a common and significant problem for people suffering from disorders of nervous system development, including fragile x syndrome. there are few validated treatments for anxiety in people with these disorders, in part because the biological basis of anxiety in neurodevelopmental disorders has not been clearly described. this study will evaluate the physiological responses of people with fragile x syndrome, down syndrome, and the fragile x premutation (a mild version of the genes that cause fragile x syndrome) to a variety of sensory, emotional, and social stimuli. by analyzing the data collected for this study, researchers aim to identify physiological characteristics linked to subgroups within the disorders, demonstrate links between physiological responses and behavioral or psychiatric symptoms, and measure physiological changes in people receiving treatment for their disorders. participation in this study will include one testing session, which will take between 3 and 3.5 hours. participants who receive treatment for their anxiety may be asked to complete this testing a second time, after their treatment. during the testing session, sensors will be placed on participants' skin in several locations to measure heart rate, sweat response, and eye-blinks. participants will then be asked to respond to multiple stimuli: sounds, lights, smells, pictures that elicit different types of emotions, an interaction with an unfamiliar person, and specialized toys. in addition, participants will undergo blood testing and have several samples of their saliva collected on the day of the testing session. participants will also be asked to collect additional saliva samples at home three times a day on 4 different days. child participants and their parents may also be asked to complete questionnaires and interviews about behavioral and emotional problems.

Eligibility criteria:
inclusion criteria: * fragile x premutation or fragile x syndrome, measured by dna testing; down syndrome, confirmed by chromosomal analysis; or normally developing control * normal hearing

Keywords: fragile x premutation fragile x syndrome down syndrome